CLINICAL TRIALS AND OUTCOMES STUDIES
The following describes some of the ongoing research in the Division of Immunology and Rheumatology
Dr. Genovese is founder and director of the Clinical Trials research group in the Division of Immunology and Rheumatology and his research is in the areas of clinical trials, outcomes, and biomarkers. His current focus includes studies of Rheumatoid Arthritis, Psoriatic Arthritis, and Osteoarthritis. He hasextensive experience designing, implementing, coordinating, and evaluating studies, data, and sample collection in autoimmune diseases and osteoarthritis (OA). As a principal investigator on over 100 studies at the Stanford University Medical School, he has been responsible for all aspects of projects, including the initial conceptualization and design of investigator-initiated, as well as multi-center, clinical studies. He previously served as Co-PI of the Stanford site of the NIAID-funded Autoimmunity Center of Excellence (ACE) and of the previously NIAMS-funded TETRAD Network. Therapies under study have included biologic response modifiers such as anti-cytokine therapies and have also included vaccines, oral toleragens, inhibitors of co-stimulation, and small molecule enzyme inhibitors. In addition to clinical investigation focused on therapeutic intervention, further studies have reflected collaborative efforts directed toward the identification of biomarkers and characterization of autoantibody development in the setting of autoimmune diseases.